Acrivon director receives 20,275 stock options

Acrivon Therapeutics director Michael John Tomsicek received a stock option grant covering 20,275 shares of common stock.

Rhea-AI Filing Summary

Acrivon Therapeutics director Michael John Tomsicek received a stock option grant covering 20,275 shares of common stock. The option has an exercise price of $1.52 per share and expires on June 16, 2036. All 20,275 option shares are reported as held directly after this grant. The filing states that these options will vest on the date immediately preceding Acrivon’s next annual meeting of stockholders, provided he remains in continuous service through that vesting date. This is a compensation-related award and does not reflect an open-market purchase or sale of shares.

Insider Trade Summary

Grant/Award: 20,275 shares

Grant/Award 1 txn

Insider TOMSICEK MICHAEL JOHN

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	20,275	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 20,275 contracts (Direct)

Footnotes (1)

1. F1. The shares subject to the option shall vest on the date immediately preceding the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service through the applicable vesting date.

Key Figures

Option grant size: 20,275 shares Exercise price: $1.52 per share Expiration date: June 16, 2036 +2 more

5 metrics

Option grant size 20,275 shares Stock Option (Right to Buy) granted to director

Exercise price $1.52 per share Conversion/exercise price of stock option

Expiration date June 16, 2036 Option expiration for director grant

Holdings after transaction 20,275 option shares Total derivative shares following grant

Transaction price per option $0.00 Grant awarded at no cost to director

Key Terms

Stock Option (Right to Buy), Grant, award, or other acquisition, derivative security, exercise price, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)""

Grant, award, or other acquisition financial

"transaction_code_description: "Grant, award, or other acquisition""

derivative security financial

"transaction_type: "derivative" for the option grant"

A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.

exercise price financial

"conversion_or_exercise_price of $1.5200 per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"options vest before the Issuer's next annual meeting of stockholders"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Acrivon Therapeutics (ACRV) director Michael John Tomsicek report on this Form 4?

He reported receiving a stock option grant for 20,275 shares of Acrivon common stock. The award is compensation-related, giving him the right to buy shares at a fixed price if and when the options vest.

What are the key terms of Michael John Tomsicek’s ACRV stock option grant?

The option covers 20,275 shares of common stock at an exercise price of $1.52 per share. It is a derivative security that expires on June 16, 2036, if not exercised before that date.

When do the ACRV stock options granted to Michael John Tomsicek vest?

The options vest on the date immediately preceding Acrivon’s next annual meeting of stockholders. Vesting is contingent on his continuous service with the company through that specified vesting date.

Does this ACRV Form 4 show Michael John Tomsicek buying or selling shares on the market?

No, it shows a grant of stock options as compensation, not an open-market trade. The transaction code “A” reflects a grant or award acquisition, and no buying or selling of existing shares is reported.

How many ACRV option shares does Michael John Tomsicek hold after this transaction?

After the grant, he holds 20,275 option shares directly according to the filing. These options relate to an equivalent number of underlying Acrivon common shares, subject to vesting and exercise conditions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/22/2026 - 04:14 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

TOMSICEK MICHAEL JOHN

(Last) (First) (Middle)

C/O ACRIVON THERAPEUTICS, INC.

480 ARSENAL WAY, SUITE 100

(Street)

WATERTOWN MASSACHUSETTS 02472

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Acrivon Therapeutics, Inc. [ ACRV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$1.52	06/17/2026		A		20,275		(1)	06/16/2036	Common Stock	20,275	$0	20,275	D

Explanation of Responses:

1. The shares subject to the option shall vest on the date immediately preceding the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service through the applicable vesting date.

	/s/ Adam D. Levy, Attorney-in-Fact	06/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)